ASH launches new clinical practice guidelines for venous thromboembolism



VTE includes deep vein thrombosis (DVT), a blood clot that usually forms in the deep veins of the leg, and pulmonary embolism (PE), a life-threatening condition when a clot breaks free and becomes clogged in the arteries of the lung. Blood clots can affect anyone, from healthy people to people with chronic diseases, in diverse settings, including pregnant women, children and hospitalized people, which means that the burden of prevention, diagnosis and effective treatment falls on a wide range of doctors

The American Society of Hematology, the world's largest professional society that deals with the causes and treatment of blood disorders, has long recognized the need for a comprehensive set of guidelines on the treatment of VTE to help to the medical community to better manage this serious illness. In association with the McMaster University The GRADE Center, a world leader in the development of guidelines and an authority on thrombosis, brought together more than 100 experts, including hematologists, other clinicians, guideline development specialists and patient representatives to meet this challenge. Today, ASH announced the results of its collective efforts, the ASH 2018 Clinical Practice Guidelines on Venous Thromboembolism, at a press event scheduled for the publication of the first six chapters of the Society's peer-reviewed journal. Blood advances. Four more chapters are in development.

"In recent years, a large body of evidence has been generated to guide the prevention, diagnosis and treatment of VTE, but approaches are often applied inconsistently." The ASH guidelines of 2018 took into account the evidence most recent to make recommendations that in some cases will reinforce existing best practices and in other cases they will change the practice, "he said. Adam Cuker, MD, MS, Chair, ASH VTE Guidelines Coordination Panel and HIT Panel and Clinical Director of the Penn Blood Disorders Center and Director of the Penn Comprehensive Thrombosis and Hemophilia Program, University of Pennsylvania in Philadelphia. "ASH believes it is essential to provide updated treatment guidelines that reflect this increased knowledge and can help the medical community better prevent, diagnose and treat VTE."

The 10 chapters of evidence-based clinical guidelines cover VTE through a series of lenses, in areas where there is currently uncertainty and variation in clinical practice:

  • Prophylaxis for hospitalized and non-hospitalized medical patients.
  • VTE diagnosis
  • Optimal management of anticoagulant therapy.
  • Heparin-induced thrombocytopenia
  • VTE in the context of pregnancy
  • Treatment of pediatric VTE
  • Treatment of deep vein thrombosis and pulmonary embolism (planned in 2019)
  • VTE in patients with cancer (scheduled for 2019)
  • Thrombophilia (scheduled for 2019)
  • Prevention of VTE in surgical patients (planned in 2019)

The ASH guidelines of 2018 were developed using cutting-edge methodology to ensure that they meet the highest standards of reliability and transparency. The panels were explicit on how the recommendations were determined and opened on the quality of the evidence that influenced the final decision-making process.

"McMaster University is the birthplace of evidence-based medicine and is an international leader in guidelines methodology, "said Holger Sch√ľnemann, MD, PhD, Vice President, ETV Guidelines and Principal Investigator, Systematic Review Team and Methods and Chair of the Department of Research Methods in Health, Evidence and Impact in McMaster University in Hamilton, Ontario. "In this partnership with ASH, we apply an advanced methodology to ensure the production of guidelines that meet the highest standards of rigor and credibility that would be useful for doctors and improve the quality of care received by our patients."

ASH is well positioned to convene a diverse set of VTE clinical experts, as well as patient representatives, who work together in the guidance panels.

"Hematologists are not the only medical professionals who diagnose and treat VTE," said Dr. Cuker. "This is the reason why we feel it is so important to collaborate with a large section of doctors from other disciplines who also serve in the front line to improve VTE results." Their perspectives and those of our patient representatives were fundamental to this. process".

The ASH guidelines of 2018 are the first of a broader guidelines development initiative for ASH, which includes a commitment to timely update of existing guidelines and the development of new ones in a variety of blood conditions.

About the American Society of Hematology (ASH)

The American Society of Hematology (ASH) (www.hematology.org) is the world's largest professional hematology society dedicated to improving the understanding, diagnosis, treatment and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline through the promotion of research, patient care, education, training and promotion in hematology. ASH publishes Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online. In 2016, ASH launched Blood advances (www.bloodadvances.org), a peer-reviewed online open-access journal.

SOURCE The American Society of Hematology (ASH)

.


Source link

Check Also

Genetically engineered babies and cloned monkeys: China tests bioethics

HONG KONG: A Chinese scientist's claim that he created the world's first genetically modified babies …